Samsung Bioepis, Harrow Partner on Eye Biosimilars in U.S.
July 17, 2025
BYOOVIZ, approved by the FDA in September 2021 as the first ophthalmology biosimilar in the US, has been commercially available since June 2022 Samsung Bioepis